| Cheng, Peng |
NCT05487976: Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor |
|
|
| Recruiting | 3 | 50 | RoW | Recombinant human activated coagulation factor VII for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A, Hemophilia B | 04/23 | 04/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors |
|
|
| Recruiting | 3 | 111 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | 10/26 | 12/26 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
| Guo, Huailian |
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants |
|
|
| Completed | 3 | 241 | RoW | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd | Acute Migraine | 02/24 | 02/24 | | |
